Nutrition & DietTirzepatide Activates Brown Fat to Burn Calories Beyond Appetite Suppression
Tirzepatide, the drug behind Mounjaro and Zepbound, may fight obesity through a second mechanism: activating brown adipose tissue, the body's calorie-burning fat. Researchers at the University of Barcelona fed obese mice a high-fat diet, treated some with tirzepatide, and controlled food intake in both groups to isolate direct drug effects. Tirzepatide-treated mice showed increased brown fat activity, greater capacity to burn glucose and fat, and higher production of batokines — molecules that benefit metabolism. This suggests the drug's impressive results aren't solely due to appetite suppression. If confirmed in humans, these findings could reshape how we understand and treat obesity and type 2 diabetes, and open doors to therapies that specifically target brown fat activation for metabolic health.
